Oral Small-Molecule GLP-1 Receptor Agonists: Mechanistic Insights and Emerging Therapeutic Strategies

Oral Small-Molecule GLP-1 Receptor Agonists: Mechanistic Insights and Emerging Therapeutic Strategies

Small-molecule glucagon-like peptide-1 receptor agonists (GLP-1RAs) represent an innovative advancement in oral therapeutics, addressing key limitations associated with injectable peptide-based incretin therapies. These nonpeptidic agents exert their actions primarily through non-canonical binding o...

Full description

Saved in:

Bibliographic Details
Main Authors:	Héctor Iván Saldívar-Cerón, Jorge Arturo Vargas-Camacho, Sonia León-Cabrera, Paola Briseño-Díaz, Ari Evelyn Castañeda-Ramírez, Axel Eduardo Muciño-Galicia, María Regina Díaz-Domínguez
Format:	Article
Language:	English
Published:	MDPI AG 2025-06-01
Series:	Scientia Pharmaceutica
Subjects:	GLP-1 receptor agonists small-molecule therapeutics biased agonism orforglipron danuglipron aleniglipron
Online Access:	https://www.mdpi.com/2218-0532/93/2/26
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Treatment with orforglipron, an oral glucagon like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetes
by: Sean Wharton, et al.
Published: (2025-06-01)

Ancient Greek Theatre and Agonistic Culture
by: Özge Acar
Published: (2022-12-01)

A GLP-1 analogue optimized for cAMP-biased signaling improves weight loss in obese mice
by: Jonathan D. Douros, et al.
Published: (2025-10-01)

Specific loss of GIPR signaling in GABAergic neurons enhances GLP-1R agonist-induced body weight loss
by: Jordan Wean, et al.
Published: (2025-05-01)

GLP-1 receptor agonists in IBD: exploring the crossroads of metabolism and inflammation
by: Giulia Migliorisi, et al.
Published: (2025-07-01)

GLP-1 Agonists, Willpower, and Weight Stigma: A Paradigm Shift for Obesity
by: Pablo Arrona-Cardoza
Published: (2025-08-01)

Mazdutide, a dual agonist targeting GLP-1R and GCGR, mitigates diabetes-associated cognitive dysfunction: mechanistic insights from multi-omics analysisResearch in context
by: Wanqing Dong, et al.
Published: (2025-07-01)

The Impact of GLP-1 Receptor Agonists on Women's Reproductive Health: A Review
by: Marta Wolszczak, et al.
Published: (2025-06-01)

Hormonal modulation, mitochondria and Alzheimer’s prevention: the role of GLP-1 agonists and estrogens
by: Fernando Lizcano, et al.
Published: (2025-06-01)

REBOUND OBESITY AFTER GLP-1 AGONISTS DISCONTINUATION
by: Zainab M. Al-Shammaa, et al.
Published: (2025-07-01)

Exploring the Role of GLP-1 Receptor Agonists in Alzheimer’s Disease: A Review of Preclinical and Clinical Evidence
by: Lívia C. R. Teixeira, et al.
Published: (2025-01-01)

The Beneficial Effects of GLP-1 Receptor Agonists Other than Their Anti-Diabetic and Anti-Obesity Properties
by: Chenqi Lu, et al.
Published: (2024-12-01)

Pulmonary artery pressure trajectories in heart failure patients treated with GLP‐1 receptor agonists
by: Haoran Jiang, et al.
Published: (2025-08-01)

Semaglutide as a GLP-1 Agonist: A Breakthrough in Obesity Treatment
by: Rui Salvador, et al.
Published: (2025-03-01)

Dietary Recommendations for the Management of Gastrointestinal Symptoms in Patients Treated with GLP-1 Receptor Agonist
by: Gentinetta S, et al.
Published: (2024-12-01)

Role of physical activity in GLP-1 receptor agonist therapy for obesity treatment
by: Łukasz Zdziebkowski, et al.
Published: (2025-07-01)

GLP-1 receptor agonist therapy and pregnancy: Evolving and emerging evidence
by: Maria S Varughese, et al.
Published: (2025-03-01)

Potential benefits of GLP-1 receptor agonist in dialysis patients with type 2 diabetes: the need for comprehensive pharmacokinetic and hemodialysis analyses
by: Hsuan-Wen Lai, et al.
Published: (2025-03-01)

GLP-1 receptor agonists and pulmonary hypertension in diabetes: A promising therapeutic strategy
by: Arif Albulushi, et al.
Published: (2025-07-01)

Are GLP-1 Analogues a New Solution for the Treatment of NAFLD?
by: Maria Sudoł, et al.
Published: (2024-12-01)

Impact of Hospitalization on Continuation of SGLT2 Inhibitors and GLP-1 Receptor Agonists for Comorbidities in Patients with Type 2 Diabetes
by: Bethany Murphy, et al.
Published: (2025-01-01)

A Closer Look at the Dermatological Profile of GLP-1 Agonists
by: Calista Persson, et al.
Published: (2025-04-01)

Improving Reproductive Outcomes in PCOS: The Emerging Role of GLP-1 Receptor Agonists
by: Adrianna Tabeau, et al.
Published: (2025-03-01)

Contesting Consensus. Disputing Inequality: Agonistic Subjectivities in Rural Bihar
by: Indrajit Roy
Published: (2013-08-01)

Research on the effects of GLP-1 receptor agonists in treating cognitive dysfunction and gait disorders in elderly patients with diabetes
by: Yang Yang, et al.
Published: (2025-06-01)

SGLT-2 Inhibitors’ and GLP-1 Receptor Agonists’ Influence on Neuronal and Glial Damage in Experimental Stroke
by: Anna Murasheva, et al.
Published: (2024-12-01)

Long-term cancer risk in users of GLP-1 agonists in Denmark: a nationwide emulated trialResearch in context
by: Mads Gamborg, et al.
Published: (2025-08-01)

Physician Perceptions of the Safety and Efficacy of GLP-1 Receptor Agonists: Underestimation of Cardiovascular Risk Reduction and Discrepancies with Clinical Evidence
by: Srikanth Krishnan, et al.
Published: (2025-01-01)

Efficacy of GLP‐1 Receptor Agonist‐Based Therapies on Cardiovascular Events and Cardiometabolic Parameters in Obese Individuals Without Diabetes: A Meta‐Analysis of Randomized Controlled Trials
by: Yue Yin, et al.
Published: (2025-04-01)

Decreased incidence of hidradenitis suppurativa and psoriasis in diabetic patients treated with GLP-1 receptor agonists: A retrospective cohort study
by: Lauren M. Ching, BS, et al.
Published: (2025-10-01)

Relative Effectiveness and Safety of the GLP-1 (Glucagon-Like Peptide 1) Receptor Agonists, Semaglutide and Liraglutide in the Treatment of Obese Type 2 Diabetics: A Prospective Observational Cohort Study in Poland
by: Hoffmann K, et al.
Published: (2025-08-01)

Exenatide and glucagon co-infusion increases myocardial glucose uptake and improves markers of diastolic dysfunction in adults with type 2 diabetes
by: James Goodman, et al.
Published: (2025-07-01)

Pharmacovigilance analysis of neurological adverse events associated with GLP-1 receptor agonists based on the FDA Adverse Event Reporting System
by: He Chen, et al.
Published: (2025-05-01)

Liver function effects of SGLT2 inhibitor and GLP‐1 receptor agonist combination treatment in patients with type 2 diabetes (post hoc analysis of RECAP study)
by: Daisuke Tsuriya, et al.
Published: (2025-07-01)

Glucagon-like peptide 1 receptor agonists: A new approach to type 2 diabetes management
by: Lynn Lambert
Published: (2013-12-01)

Exploring a Synergistic Approach: Dual GLP-1 Agonist Combined with Degludec Basal Insulin for Early Type 1 Diabetes Treatment and its Impact on Albumin-Insulin Producing Cells Expression
by: Amr Ahmed, et al.
Published: (2024-07-01)

Differential effects of GLP-1 receptor agonists on diabetic osteopathy in type 2 diabetes: a patient-stratified network meta-analysis
by: Yazan Jumah Alalwani, et al.
Published: (2025-08-01)

Association between GLP-1 receptor agonists as a class and colorectal cancer risk: a meta-analysis of retrospective cohort studies
by: Ying Zhong, et al.
Published: (2025-08-01)

The concepts of nationality and citizenship in the XXI century’s immigration scenario: an agonistic approach
by: Michelle Gueraldi
Published: (2025-05-01)

Regimen comprising GLP-1 receptor agonist and basal insulin can decrease the effect of food on glycemic variability compared to a pre-mixed insulin regimen
by: Yi-Hsuan Lin, et al.
Published: (2022-12-01)